PAncreatic Adenocarcinoma in Hospital
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 1,204
- 试验地点
- 66
- 主要终点
- Survival
研究概览
简要总结
Few data are currently available in the literature on pancreatic adenocarcinoma in France. About 8,000 new cases each year in France. The 5-year survival for all stages combined is <5%. This is the only digestive cancer in which mortality / incidence ratio is 98%.
Epidemiological characteristics at diagnosis, the impact on the survival of recent advances related to surgery, adjuvant chemotherapy and new standard forms of adjuvant chemotherapy (FOLFIRINOX) are mispriced in real life.
The development of new drugs and the development of Phase II and III require a better understanding of the state of this disease in the country.
The main objective is to describe the characteristics of the pancreatic adenocarcinoma at diagnosis in France and make an inventory of diagnostic practices and support.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Living in France
- •Pancreatic adenocarcinoma histologically or cytologically proven
- •primary diagnosis
- •Agreed to participate
排除标准
- •Suspected pancreatic adenocarcinoma histologically or cytologically unproven
- •Refused to participate
结局指标
主要结局
Survival
时间窗: patient death (following during 5 year)
次要结局
未报告次要终点